Evaluation of the Xpert fingerstick HCV viral load assay

Accurate measurement of the hepatitis B virus (HBV) DNA is important for the management of patients with chronic HBV infection. Here, the performance of the Xpert® HBV Viral Load test (Xpert HBV Viral Load) versus the Roche COBAS® Ampliprep/COBAS® TaqMan® system (CAP/CTM HBV) HBV test v2.0 was evaluated. From September 2017 to December 2017, a total of 876 prospectively collected or archived serum or EDTA plasma specimens from subjects chronically infected with HBV were tested using the Xpert HBV Viral Load and the CAP/CTM HBV v2.0 assays. Of the 876 specimens tested, 560 were within the quantitative range of both assays. The agreement between the two methods was 90.0%. No difference in plasma or serum samples was observed. Deming regression analysis showed a good correlation of the Xpert HBV Viral Load assay with the CAP/CTM HBV v2.0 assay. The Bland–Altman analysis showed a good agreement between the results of the Xpert HBV Viral Load assay and the CAP/CTM HBV assay, with a mean difference (±1.96 standard deviation) of 0.0091 ± 0.3852 Log IU/mL. Comparing the two assays, only nineteen specimens (2.1%) had a difference greater than 1.96 times the standard deviation. The Xpert® HBV Viral Load test is suitable for monitoring patients with HBV infection and is useful in diagnostic settings.

Download Full-text

Performance of the Abbott RealTime HIV-1 Viral Load Assay Is Not Impacted by Integrase Inhibitor Resistance-Associated Mutations

Journal of Clinical Microbiology ◽

10.1128/jcm.02253-10 ◽

2011 ◽

Vol 49 (4) ◽

pp. 1631-1634 ◽

Cited By ~ 3

Author(s):

T. P. Young ◽

G. Cloherty ◽

S. Fransen ◽

L. Napolitano ◽

P. Swanson ◽

...

Keyword(s):

Viral Load ◽

Integrase Inhibitor ◽

Viral Load Assay ◽

Inhibitor Resistance ◽

Hiv 1

Download Full-text

Response : HIV Viral Load Assay

Science ◽

10.1126/science.271.5252.1043-b ◽

1996 ◽

Vol 271 (5252) ◽

pp. 1043-1043

Author(s):

Barton F. Haynes

Keyword(s):

Viral Load ◽

Hiv Viral Load ◽

Viral Load Assay

Download Full-text

Viral load assay performs comparably to early infant diagnosis assay to diagnose infants with HIV in Mozambique: a prospective observational study

Journal of the International AIDS Society ◽

10.1002/jia2.25422 ◽

2020 ◽

Vol 23 (1) ◽

Cited By ~ 1

Author(s):

Adolfo Vubil ◽

Carina Nhachigule ◽

Osvaldo Loquiha ◽

Bindiya Meggi ◽

Nedio Mabunda ◽

...

Keyword(s):

Viral Load ◽

Observational Study ◽

Prospective Observational Study ◽

Early Infant Diagnosis ◽

Early Infant ◽

Viral Load Assay

Download Full-text

Performance of a high-throughput next-generation sequencing method for analysis of HIV drug resistance and viral load

Journal of Antimicrobial Chemotherapy ◽

10.1093/jac/dkaa352 ◽

2020 ◽

Vol 75 (12) ◽

pp. 3510-3516 ◽

Cited By ~ 1

Author(s):

Jessica M Fogel ◽

David Bonsall ◽

Vanessa Cummings ◽

Rory Bowden ◽

Tanya Golubchik ◽

...

Keyword(s):

Drug Resistance ◽

Viral Load ◽

Next Generation Sequencing ◽

High Throughput ◽

Whole Genome ◽

Hiv Viral Load ◽

Viral Loads ◽

Viral Load Assay ◽

Generation Sequencing ◽

Hiv 1

Abstract Objectives To evaluate the performance of a high-throughput research assay for HIV drug resistance testing based on whole genome next-generation sequencing (NGS) that also quantifies HIV viral load. Methods Plasma samples (n = 145) were obtained from HIV-positive MSM (HPTN 078). Samples were analysed using clinical assays (the ViroSeq HIV-1 Genotyping System and the Abbott RealTime HIV-1 Viral Load assay) and a research assay based on whole-genome NGS (veSEQ-HIV). Results HIV protease and reverse transcriptase sequences (n = 142) and integrase sequences (n = 138) were obtained using ViroSeq. Sequences from all three regions were obtained for 100 (70.4%) of the 142 samples using veSEQ-HIV; results were obtained more frequently for samples with higher viral loads (93.5% for 93 samples with >5000 copies/mL; 50.0% for 26 samples with 1000–5000 copies/mL; 0% for 23 samples with <1000 copies/mL). For samples with results from both methods, drug resistance mutations (DRMs) were detected in 33 samples using ViroSeq and 42 samples using veSEQ-HIV (detection threshold: 5.0%). Overall, 146 major DRMs were detected; 107 were detected by both methods, 37 were detected by veSEQ-HIV only (frequency range: 5.0%–30.6%) and two were detected by ViroSeq only. HIV viral loads estimated by veSEQ-HIV strongly correlated with results from the Abbott RealTime Viral Load assay (R2 = 0.85; n = 142). Conclusions The NGS-based veSEQ-HIV method provided results for most samples with higher viral loads, was accurate for detecting major DRMs, and detected mutations at lower levels compared with a method based on population sequencing. The veSEQ-HIV method also provided HIV viral load data.

Download Full-text